Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects.
about
Structure based approaches for targeting non-coding RNAs with small moleculesOral administration of erythromycin decreases RNA toxicity in myotonic dystrophyMBNL proteins and their target RNAs, interaction and splicing regulation.Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.RNA Structures as Mediators of Neurological Diseases and as Drug Targets.Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type IIdentification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy.Reduction of Huntington's Disease RNA Foci by CAG Repeat-Targeting Reagents.RNA mis-splicing in disease.Myotonic dystrophy: approach to therapy.New developments in RAN translation: insights from multiple diseases.Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.Cells of Matter-In Vitro Models for Myotonic Dystrophy.Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1.miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.Insights into the development of chemical probes for RNA
P2860
Q26858823-BCFC5952-4A77-4F1B-9592-57C8624D46A0Q28272224-276DE967-221A-4AA4-B7DA-2154D7DF97A1Q34248811-B4481D79-A14F-4F25-811D-E12AC06CF586Q35682519-48FA87B0-31BB-4A29-9660-2DF1D40E2746Q35868044-7718D11D-C100-4C8D-BE38-86C69D13040AQ36051366-377B48ED-1EAD-47C7-B932-FFF2732A87D4Q36186164-817C9281-01D6-432D-85ED-FFB9C5DAF146Q36378612-ED953DAE-14B1-4F42-BB26-4E2B2DEC202FQ36392989-53BCEE6C-F79C-44D1-91B1-B9280785FAD5Q37358384-5A404BC6-08F8-4F6A-AFAC-1BAA2BD11955Q37723428-200782CB-C097-4FFB-B242-8BC0598F5DECQ38642996-7FD42A3A-3785-4C7C-918A-314970D525D9Q38855524-BFB759B3-8E91-4747-981E-C8AA57EF2C46Q39213248-215D52F6-0BC4-4164-96EA-394BBD9F1A6EQ39256785-72B7F2F6-FDB0-48C3-8162-A42A9DEAF084Q55100992-61E1BBBC-F961-4657-99B6-635D701219F5Q55240995-8355314F-AB4F-4520-BB07-B7F9B6ACCA43Q55418837-730A13A3-98D4-4E57-B29D-95D42B9856BEQ58794879-C212958E-A102-4123-BC92-009DE1634973
P2860
Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lomofungin and dilomofungin: i ...... ith distinct cellular effects.
@ast
Lomofungin and dilomofungin: i ...... ith distinct cellular effects.
@en
type
label
Lomofungin and dilomofungin: i ...... ith distinct cellular effects.
@ast
Lomofungin and dilomofungin: i ...... ith distinct cellular effects.
@en
prefLabel
Lomofungin and dilomofungin: i ...... ith distinct cellular effects.
@ast
Lomofungin and dilomofungin: i ...... ith distinct cellular effects.
@en
P2093
P2860
P50
P356
P1476
Lomofungin and dilomofungin: i ...... ith distinct cellular effects.
@en
P2093
Catherine Z Chen
Charles A Thornton
Christopher P Austin
Juan J Marugan
Leslie O Ofori
Matthew D Disney
Samarjit Patnaik
P2860
P304
P356
10.1093/NAR/GKU275
P407
P577
2014-05-05T00:00:00Z